This Product is Comprised of Raw
Linden Honey Infused with 500mg CBD / Each Jar Contains 20 Servings
(25mg CBD per Serving)
NEW YORK, NY -- December 8, 2020 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced a new product
offering to help ensure the expansion and diversification of the
Company’s proprietary product offerings. This is in
response to the Company’s fast growing E-Commerce business segment
as well as the continually increasing customer base.
After evaluating numerous potential new product offerings, the
Company has decided to launch this CBD Infused Linden Honey (“CBD
Honey”) product. This new product will be infused with
500mg of CBD per Jar (“Unit”) and each jar contains 20 servings
(25mg CBD per serving). This product will also be Kosher
Certified and of the highest quality. The Manufacturer’s
Suggested Retail Price (“MSRP”) is expected to be set at $49.99 USD
per Jar. This CBD Honey (16 oz. Jars) will be available
exclusively on the Company’s E-Commerce Website (www.taurigum.com).
Raw Linden Honey is a tough honey to produce as the Linden trees
are only in bloom 7-10 days annually. The honey has been
described as having a very fresh aroma, described as: minty,
menthol, camphor, balsamic, etc. Excellent honey for tea, desserts,
muffins, hot cereal - you name it! The blooming season
for Linden trees is generally the first week in July in the
Northern Hemisphere.
Tauriga’s CEO Seth M. Shaw: “The Company has been both pleased
and excited by the sharp increase in its online E-Commerce
business. However, even more exciting, is the continual
growth of the Company’s prospective customer base. As
the customer base increases, so does the Company’s desire to expand
and diversify product offerings to support this enhanced
audience. It is our policy to carefully listen to the
advice and recommendations of our customers. In this
spirit, the Company has decided to launch this innovative CBD Honey
product. Additionally, more products are on the
way!”
In other news, the Company is close to achieving an important
corporate milestone. The Company’s Instagram Page,
@taurigum, has secured more than 9,700 Followers. Once
the 10,000 Followers threshold is reached, the Company believes
that there will be a positive effect on its E-Commerce
Business.
Link to @taurigum Instagram Page:
Link: https://www.instagram.com/taurigum/
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) &
(Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear
Bellini). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce website:
www.taurigum.com). Please visit our corporate website, for
additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates
to the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March 18,
2020, the Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. The second one relates to a
collaboration agreement with Aegea Biotechnologies Inc. for the
co-development of a rapid, multiplexed, Novel Coronavirus
(COVID-19) test with superior sensitivity and selectivity.
On October 6, 2020, the Company announced that it has been
approved to operate as a U.S. Government Vendor (CAGE CODE #
8QXV4)
On October 7, 2020 the Company disclosed a Strategic Alliance
with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace,
Son of Christopher “The Notorious B.I.G.” Wallace.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the
Company operates a full time E-Commerce fulfillment center located
in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024